<DOC>
	<DOCNO>NCT00795769</DOCNO>
	<brief_summary>RATIONALE : Ondansetron may help lessen prevent nausea vomit patient undergoing stem cell transplant . PURPOSE : This phase II trial study well ondansetron work prevent nausea vomit patient undergoing stem cell transplant .</brief_summary>
	<brief_title>Ondansetron Preventing Nausea Vomiting Patients Undergoing Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : I . To determine whether incidence nausea , retch vomit related administration autologous hematopoetic stem cell cryopreserved DMSO reduce use single dose intravenous ondansetron prior stem cell infusion . II . To determine number patient experience nausea vomit . OUTLINE : Patients receive ondansetron IV 30-60 minute undergo autologous peripheral blood stem cell transplantation .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Germinoma</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Neutrophilic , Chronic</mesh_term>
	<mesh_term>Trophoblastic Neoplasms</mesh_term>
	<mesh_term>Gestational Trophoblastic Disease</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Inclusion Autologous PBSC transplant patient Englishspeaking Planned cryopreserved PBSC infusion SCCA outpatient clinic Exclusion History prior autologous transplant NonEnglishspeaking Planned cryopreserved PBSC infusion UWMC inpatient unit Infusion cryopreserved PBSC thaw wash remove DMSO prior infusion Allergy adverse reaction ondansetron</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>